a primer on the current state-of-the-science neoadjuvant and adjuvant therapy for patients with locally advanced rectal adenocarcinomas一个引物对当前尖端科学新辅助和辅助治疗局部晚期患者直肠腺癌.pdfVIP

Hindawi Publishing Corporation International Journal of Surgical Oncology Volume 2012, Article ID 863034, 7 pages doi:10.1155/2012/863034 Review Article A Primer on the Current State-of-the-Science Neoadjuvant and Adjuvant Therapy for Patients with Locally Advanced Rectal Adenocarcinomas Jeffrey T. Yorio,1 Nishin A. Bhadkamkar,2 Bryan K. Kee,1 and Christopher R. Garrett1 1 Unit 426, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030-4009, USA 2 Unit 462, Department of General Oncology, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030-4009, USA Correspondence should be addressed to Christopher R. Garrett, cgarrett@ Received 9 February 2012; Accepted 23 February 2012 Academic Editor: Nikolaos Touroutoglou Copyright © 2012 Jeffrey T. Yorio et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Patients with rectal cancers, due to the unique location of the tumor, have a recurrence pattern distinct from colon cancers. Advances in adjuvant therapy over the last three decades have played an important role in improving patient outcomes. This article serves to review the clinical studies that lay the basis for our current standard-of-care treatment of patients with locally advanced rectal cancer, as well as touch upon future ongoing experimental clinical trials of adjuvant chemoradiation therapy. 1. Introduction the high rate of locally recurrent disease, multimodality therapy with